More positive data on icotrokinra have lent support to Johnson & Johnson’s claim that its first-in-class oral therapy has to potential to set a new standard of treatment in plaque psoriasis.
Key Takeaways
- Data presented at the AAD meeting showed that nearly half of patients treated with icotrokinra achieved completely clear skin
- The once-daily oral peptide that blocks the interleukin-23 receptor is showing efficacy that is not miles off the injectables and excellent tolerability
At a busy American Academy of Dermatology meeting in Orlando for the healthcare giant, J&J presented more data from the Phase III ICONIC-LEAD trial of icotrokinra. These followed the topline results published in November which showed that at week 16, 64.7% of patients taking the once-daily oral peptide that blocks the interleukin-23 receptor achieved clear or almost clear skin measured using the Investigator’s Global Assessment (IGA) scale, ie, a score of 0 or 1, while 49
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?